For research use only. Not for therapeutic Use.
Nitroxoline（Cat No.:I003459）is a synthetic antimicrobial agent in the hydroxyquinoline family, primarily used to treat urinary tract infections. It acts by inhibiting bacterial DNA synthesis and enzyme activity, showing effectiveness against Gram-positive and Gram-negative bacteria, as well as some fungi. Nitroxoline’s broad spectrum includes pathogens like E. coli, Staphylococcus saprophyticus, and Proteus mirabilis. Known for its good tissue penetration and urinary excretion, it reaches high concentrations in the urinary tract, enhancing its efficacy. Nitroxoline remains valuable in targeted urinary infections and as a research tool for studying microbial inhibition.
| Catalog Number | I003459 |
| CAS Number | 4008-48-4 |
| Synonyms | 5-nitroquinolin-8-ol |
| Molecular Formula | C9H6N2O3 |
| Purity | ≥95% |
| Target | Apoptosis |
| Solubility | DMSO: ≥ 2 mg/mL |
| Storage | Room temperature |
| IUPAC Name | 5-nitroquinolin-8-ol |
| InChI | InChI=1S/C9H6N2O3/c12-8-4-3-7(11(13)14)6-2-1-5-10-9(6)8/h1-5,12H |
| InChIKey | RJIWZDNTCBHXAL-UHFFFAOYSA-N |
| SMILES | C1=CC2=C(C=CC(=C2N=C1)O)[N+](=O)[O-] |
| Reference | </br>1:[On the treatment of candiduria and nitroxoline sensitivity of Candida isolates]. Vahlensieck W.Urologe A. 2017 May;56(5):658. doi: 10.1007/s00120-017-0377-5. German. No abstract available. PMID: 28424828 </br>2:Nitroxoline shows antimyeloma activity by targeting the TRIM25/p53 axle. Mao H, Du Y, Zhang Z, Cao B, Zhao J, Zhou H, Mao X.Anticancer Drugs. 2017 Apr;28(4):376-383. doi: 10.1097/CAD.0000000000000466. PMID: 28301380 </br>3:Nitroxoline: a broad-spectrum biofilm-eradicating agent against pathogenic bacteria. Abouelhassan Y, Yang Q, Yousaf H, Nguyen MT, Rolfe M, Schultz GS, Huigens RW 3rd.Int J Antimicrob Agents. 2017 Feb;49(2):247-251. doi: 10.1016/j.ijantimicag.2016.10.017. Epub 2016 Dec 6. PMID: 28110918 </br>4:[Nitroxoline – an option for the antibiotic treatment of urinary tract infections]. Hof H, Bertsch D, Passek D, Schwarz R.Urologe A. 2017 Feb;56(2):167-171. doi: 10.1007/s00120-016-0218-y. German. PMID: 27596848 </br>5:Lab-on-a-Chip-Surface Enhanced Raman Scattering Combined with the Standard Addition Method: Toward the Quantification of Nitroxoline in Spiked Human Urine Samples. Hidi IJ, Jahn M, Weber K, Bocklitz T, Pletz MW, Cialla-May D, Popp J.Anal Chem. 2016 Sep 20;88(18):9173-80. doi: 10.1021/acs.analchem.6b02316. Epub 2016 Sep 8. PMID: 27570877 </br>6:Preclinical pharmacodynamic evaluation of antibiotic nitroxoline for anticancer drug repurposing. Zhang QI, Wang S, Yang D, Pan K, Li L, Yuan S.Oncol Lett. 2016 May;11(5):3265-3272. Epub 2016 Mar 29. PMID: 27123101 Free PMC Article</br>7:Synthesis of 8-heteroaryl nitroxoline analogues via one-pot sequential Pd-catalyzed coupling reactions. Brodnik H, Požgan F, Štefane B.Org Biomol Chem. 2016 Feb 14;14(6):1969-81. doi: 10.1039/c5ob02364e. PMID: 26754567 </br>8:Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation. Chang WL, Hsu LC, Leu WJ, Chen CS, Guh JH.Oncotarget. 2015 Nov 24;6(37):39806-20. doi: 10.18632/oncotarget.5655. PMID: 26447757 Free PMC Article</br>9:Structure-based development of nitroxoline derivatives as potential multifunctional anti-Alzheimer agents. Knez D, Brus B, Coquelle N, Sosič I, Šink R, Brazzolotto X, Mravljak J, Colletier JP, Gobec S.Bioorg Med Chem. 2015 Aug 1;23(15):4442-52. doi: 10.1016/j.bmc.2015.06.010. Epub 2015 Jun 14. PMID: 26116179 </br>10:Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells. Chan-On W, Huyen NT, Songtawee N, Suwanjang W, Prachayasittikul S, Prachayasittikul V.Drug Des Devel Ther. 2015 Apr 8;9:2033-47. doi: 10.2147/DDDT.S79313. eCollection 2015. PMID: 25897210 Free PMC Article |
